FOLH1 and prostate carcinoma: PSMA is now incorporated in biochemical recurrence guidelines of American Urology Association Radiographic Assessments for Detection of Advanced Recurrence (RADAR III) consensus group [53], European association of urology [54] and the NCCN guidelines for prostate cancer [55].